Close
Nordic 9Nordic 9

Versant Ventures (investor - Venture Capital)

United States versantventures.com
See something wrong or missing? Let us know
Offices:San Francisco
Average round investment:62.97M USD
Average number per year:1.8
Distribution: 2025 (1)2024 (3)2023 (2)2022 (2)2021 (1)
Portfolio companies: Switzerland Granite BioDenmark Antag TherapeuticsSwitzerland Bright Peak Therapeutics See the entire list
Mostly invests in: Switzerland Switzerland (7) Health services (9)
See the entire list

Showing 3 of 9 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Versant Ventures mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Versant Ventures

Name Criteria
United States SR One
92%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Switzerland, Denmark, United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Arch Venture Partners
92%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United States Woodline Partners
91%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Japan SBI Holdings
91%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Switzerland, Denmark, United Kingdom
  • Average number of deals per year: 3.8
  • Active last 12 months: Yes
France Lauxera Capital Partners
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Denmark, United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Switzerland HBM Healthcare Investments
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Switzerland, Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Denmark Maj Invest
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Denmark
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Venrock
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Switzerland, Denmark, United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Switzerland Pictet Group
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Switzerland, Denmark, United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
United Kingdom IAG Silverstripe
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Top